World News: 14:00 GMT Wednesday 17th April 2019. [INmune BIO, Inc. via Globe Newswire via SPi World News]
LA JOLLA, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- (NASDAQ: ), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Christopher Barnum, Ph.D., Director of Neuroscience and Translational Medicine, will be presenting a poster at the in Boston on April 17. The poster will address the Phase 1b trial on the company’s drug candidate XPro1595 for patients with mild to moderate Alzheimer’s disease.
”Because of our focus on neuroinflammation as a cause of neurologic disease, we have designed a Phase 1 trial that measures traditional and novel biomarkers of inflammation as a first step in our Alzheimer’s disease program,” said Dr. Barnum. “We are looking forward to sharing our ideas with the neurology drug development experts at the conference.”
The poster presentation is titled “Phase 1b open-label, biomarker-directed study of the brain penetrant, soluble selective inhibitor of soluble tumor necrosis factor (TNF) XPro1595 in patients with mild to moderate Alzheimer’s disease.” XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. The poster describes the clinical trial, addressing the inclusion criteria, biomarker strategy and end-points, as well as the way XPro1595 targets soluble TNF.
The Neuroimmunology Drug Development Summit brings together neuroimmunology and neuroinflammation experts from the field’s most active and innovative pharmaceutical and biotech companies.
Globe Newswire: 14:00 GMT Wednesday 17th April 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.